Tags

Type your tag names separated by a space and hit enter

Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
Urol Int. 2007; 79(4):356-60.UI

Abstract

BACKGROUND

The objective of this study was to evaluate the adequacy in calculating prostate-specific antigen doubling time (PSADT) using an ultrasensitive assay of prostate-specific antigen (PSA) for biochemical failure after radical prostatectomy (RP).

METHODS

In this research, we included 52 consecutive patients who experienced more than or equal to three consecutive increases in ultrasensitive PSA values after RP at two institutions. PSADT is to be calculated by fitting a linear model to post-nadir longitudinal logarithm ultrasensitive PSA (lnPSA) values. The goodness of fit of linear model for longitudinal lnPSA values was evaluated by applying a mixed effect model for all patients or two groups divided by median PSADT.

RESULTS

Median PSADT was 4.7 months. A mixed effect model showed that the fit of linear model for longitudinal lnPSA values was not good in lower ultrasensitive PSA values for all patients (p < 0.0001) or the group with a value longer than the median PSADT (p < 0.0001), while it was not worse for the group with a value shorter than the median PSADT (p = 0.079).

CONCLUSIONS

These findings suggest that calculating PSADT using an ultrasensitive assay for biochemical failure after RP may still be open for discussion.

Authors+Show Affiliations

Department of Urology, Juntendo University, Tokyo, Japan. fshimizu-jua@umin.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18025856

Citation

Shimizu, Fumitaka, et al. "Inadequacy of Prostate-specific Antigen Doubling Time Estimates Calculated Using an Ultrasensitive Assay of Prostate-specific Antigen for Biochemical Failure After Radical Prostatectomy." Urologia Internationalis, vol. 79, no. 4, 2007, pp. 356-60.
Shimizu F, Matsuyama Y, Tominaga T, et al. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy. Urol Int. 2007;79(4):356-60.
Shimizu, F., Matsuyama, Y., Tominaga, T., Ohashi, Y., & Fujime, M. (2007). Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy. Urologia Internationalis, 79(4), 356-60.
Shimizu F, et al. Inadequacy of Prostate-specific Antigen Doubling Time Estimates Calculated Using an Ultrasensitive Assay of Prostate-specific Antigen for Biochemical Failure After Radical Prostatectomy. Urol Int. 2007;79(4):356-60. PubMed PMID: 18025856.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy. AU - Shimizu,Fumitaka, AU - Matsuyama,Yutaka, AU - Tominaga,Takashi, AU - Ohashi,Yasuo, AU - Fujime,Makoto, PY - 2006/08/28/received PY - 2007/01/28/accepted PY - 2007/11/21/pubmed PY - 2008/1/3/medline PY - 2007/11/21/entrez SP - 356 EP - 60 JF - Urologia internationalis JO - Urol. Int. VL - 79 IS - 4 N2 - BACKGROUND: The objective of this study was to evaluate the adequacy in calculating prostate-specific antigen doubling time (PSADT) using an ultrasensitive assay of prostate-specific antigen (PSA) for biochemical failure after radical prostatectomy (RP). METHODS: In this research, we included 52 consecutive patients who experienced more than or equal to three consecutive increases in ultrasensitive PSA values after RP at two institutions. PSADT is to be calculated by fitting a linear model to post-nadir longitudinal logarithm ultrasensitive PSA (lnPSA) values. The goodness of fit of linear model for longitudinal lnPSA values was evaluated by applying a mixed effect model for all patients or two groups divided by median PSADT. RESULTS: Median PSADT was 4.7 months. A mixed effect model showed that the fit of linear model for longitudinal lnPSA values was not good in lower ultrasensitive PSA values for all patients (p < 0.0001) or the group with a value longer than the median PSADT (p < 0.0001), while it was not worse for the group with a value shorter than the median PSADT (p = 0.079). CONCLUSIONS: These findings suggest that calculating PSADT using an ultrasensitive assay for biochemical failure after RP may still be open for discussion. SN - 1423-0399 UR - https://www.unboundmedicine.com/medline/citation/18025856/Inadequacy_of_prostate_specific_antigen_doubling_time_estimates_calculated_using_an_ultrasensitive_assay_of_prostate_specific_antigen_for_biochemical_failure_after_radical_prostatectomy_ L2 - https://www.karger.com?DOI=10.1159/000109723 DB - PRIME DP - Unbound Medicine ER -